[EGF receptors in urological cancer. Molecular basis and therapeutic involvements].
Many epithelial cancers have been found to overexpress the receptor to epidermal growth factor (EGFR) including head and neck, breast, colon, lung, prostate, kidney, ovary, brain, pancreas and bladder cancer. Because of the association of EGFR overexpression with overall poor prognosis in patients with cancer, a number of strategies to block or downregulate EGFR have been developed to inhibit tumor proliferation and improve clinical outcome. These include monoclonal antibodies directed against the EGFR such as IMC-C225 which specifically targets EGFR and ZD 1839 (Iressa) capable of inhibiting EGFR tyrosine-kinase in vitro. This report will focus on antibodies that target EGFR in renal cell carcinoma, prostate cancer and bladder cancer.
Paule
Bernard
B
Service d'Urologie, Hôpital Henri-Mondor, 54, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil.
Brion
Nathalie
N
D066246:ErbB Receptors / Q000096:biosynthesis / Q000502:physiology*; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000209:etiology / Q000235:genetics; D014571:Urologic Neoplasms / Q000209:etiology* / Q000235:genetics
D066246:ErbB Receptors